TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03988140

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental Implant Placement and subsequent prosthetic reabilithation
Description: Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement and subsequent prosthetic reabilithation
Description: Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
Study: NCT03666416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
Study: NCT04279080

Intervention type: OTHER
Intervention: low anterior resection syndrome evaluation
Description: evaluation of postoperative functional bowel outcome

Intervention type: OTHER
Intervention: low anterior resection syndrome evaluation
Description: evaluation of postoperative functional bowel outcome
Study: NCT05897866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management
Description: Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
Study: NCT04354415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel or trigger finger release
Description: Carpal tunnel or trigger finger release with and without the use of tourniquet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel or trigger finger release
Description: Carpal tunnel or trigger finger release with and without the use of tourniquet
Study: NCT04530669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Tone Power Therapy
Description: High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise program
Description: physical therapy conventional selected exercise program inform of functional activities of daily living

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: physical therapy conventional selected exercise program inform of functional activities of daily living
Study: NCT01299883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated vs Non-integrated Risk Education
Description: Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated vs Non-integrated Risk Education
Description: Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
Study: NCT03452462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing
Description: Programming of either Direct His Bundle pacing or biventricular pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing
Description: Programming of either Direct His Bundle pacing or biventricular pacing
Study: NCT03297229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
Study: NCT01609062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
Study: NCT01436253

Intervention type: BEHAVIORAL
Intervention: Lifestyle Changes
Description: Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.

Intervention type: DRUG
Intervention: Hypolipemics
Description: Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
Study: NCT03408977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probe meal
Description: The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probe meal
Description: The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
Study: NCT00081822

Intervention type: DRUG
Group type: OTHER
Intervention: clofarabine
Description: Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.

Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.
Study: NCT03399851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amplatzer Amulet for left atrial appendage closure
Description: The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Watchman/FLX for left atrial appendage closure
Description: The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
Study: NCT04152057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate Tablets
Description: 400mg/d,po qd,q3w, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: 125mg/m2,ivggt,d1,q3w,4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
Study: NCT00623805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution in single-use vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution in single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was supplied as a lyophilized powder in vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin was supplied as a lyophilized powder in vials.
Study: NCT05039294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Physical Activity Educational Program
Description: The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
Study: NCT04190836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Managed Exercise Strategy
Description: The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
Study: NCT03517449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg administered orally (PO) QD during each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
Study: NCT02626455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
Study: NCT03297229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values.
Study: NCT02626455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
Study: NCT01803087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Study: NCT01115179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 10%
Description: Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
Study: NCT03166995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low impact aerobic exercise
Description: The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
Study: NCT01803087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI (Foster®) (CTR)
Study: NCT00777868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Strength IDP-108
Description: Topical application once a day for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-108
Description: Topical application once a day for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-108 under occlusion
Description: Topical application once a day for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application once a day for 9 months
Study: NCT04870021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),
Description: recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Short text messages and calls to parents for compliance to routine immunization schedule
Description: After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short text messages and calls to parents for compliance to routine immunization schedule
Description: After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
Study: NCT00189163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg, taken orally, once per day, for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar Pill, taken orally, once per day, for 48 weeks
Study: NCT02990013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avenova
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5% solution
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
Study: NCT01029262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)